Immunotherapy最新文献_第4页

Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors. 血清白蛋白-肌酐比值作为免疫检查点抑制剂治疗患者的生物标志物的预后价值

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-05 DOI: 10.1080/1750743X.2025.2513850

Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar

{"title":"Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors.","authors":"Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar","doi":"10.1080/1750743X.2025.2513850","DOIUrl":"10.1080/1750743X.2025.2513850","url":null,"abstract":"Background: Albumin and creatinine are considered important for understanding patient response to immune checkpoint inhibitors (ICIs). However, numerous confounding factors complicate the interpretation of albumin and creatinine alone in clinical practice. This study aims to assess the correlation between survival outcomes and serum-albumin creatinine ratio (sACR) in patients treated with ICIs.Methods: This study was conducted on individuals who received at least three doses of ICI between 2018 and 2023. Patients were divided into two groups, sACR-High and sACR-Low, based on the median level. The relationship between sACR and survival outcomes was analyzed using a cox regression model. The relationship between sACR and early progression, late progression, and long-term benefit was analyzed using a logistic regression model.Results: Patients with lower sACR had decreased overall survival (OS) (HR: 1.42, 95% CI 1.07-1.89, p = 0.014) and progression-free survival (PFS) (HR: 1.34, 95% CI 1.08-1.66, p = 0.009). sACR was associated with early progression (HR: 1.86, 95% CI, 1.14-3.01, p = 0.012), late progression (HR: 2.06, 95 % CI 1.0-4.24, p = 0.050), and long-term benefit of ICIs (HR: 1.72, 95% CI 1.002-2.93, p = 0.049).Conclusions: Our study demonstrated that sACR could serve as an independent predictor of OS, PFS, early progression, late progression, and long-term benefit in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"567-575"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies. Pegcetacoplan用于治疗因年龄相关性黄斑变性引起的地理萎缩：OAKS和DERBY临床研究的简单语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-01-17 DOI: 10.1080/1750743X.2025.2449760

Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, David Boyer, Federico Grossi, Caroline R Baumal, Jean-Francois Korobelnik, Jason S Slakter, Nadia K Waheed, Ravi Metlapally, Ian Pearce, Nathan Steinle, Anibal A Francone, Allen Hu, David R Lally, Pascal Deschatelets, Cedric Francois, Caleb Bliss, Giovanni Staurenghi, Jordi Monés, Rishi P Singh, Ramiro Ribeiro, Charles C Wykoff

引用次数: 0

Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors. 白蛋白-肌骨化症作为免疫检查点抑制剂治疗患者的预后生物标志物。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-27 DOI: 10.1080/1750743X.2025.2525743

Taha Koray Sahin, Deniz Can Guven, Yakup Ozbay, Firat Atak, Sevtap Arslan, Mehmet Cihan İcli, Latif Karahan, Yunus Kaygusuz, Zafer Arik, Omer Dizdar, Mustafa Erman, Suayib Yalcin, Mehmet Ruhi Onur, Sercan Aksoy

{"title":"Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors.","authors":"Taha Koray Sahin, Deniz Can Guven, Yakup Ozbay, Firat Atak, Sevtap Arslan, Mehmet Cihan İcli, Latif Karahan, Yunus Kaygusuz, Zafer Arik, Omer Dizdar, Mustafa Erman, Suayib Yalcin, Mehmet Ruhi Onur, Sercan Aksoy","doi":"10.1080/1750743X.2025.2525743","DOIUrl":"10.1080/1750743X.2025.2525743","url":null,"abstract":"Background: Although immune checkpoint inhibitors (ICIs) have heralded a new era in cancer treatment, many patients do not respond, underscoring the need for biomarkers. The albumin-myosteatosis gauge (AMG) is a recently developed integrated measure of myosteatosis and serum albumin levels, reflecting systemic inflammation and malnutrition. Herein, we investigate the prognostic value of AMG in patients with advanced cancer treated with ICIs.Methods: A total of 308 patients with advanced cancer treated with ICIs were included. Skeletal muscle index and skeletal muscle radiodensity (SMD) were measured from computed tomography images obtained at the level of the L3 vertebra. The AMG was calculated by multiplying SMD by albumin and expressed as an arbitrary unit.Results: The median age (interquartile range) was 63 (55-70), and 198 (64.3%) were male. Non-small cell lung cancer (NSCLC) was the most common primary cancer (28.2%), followed by RCC (20.8%) and melanoma (20.2%). Multivariable analyses revealed that lower AMG values were independently associated with decreased OS (HR:1.37; 95%CI:1.03-1.82; p = 0.032) and PFS (HR:1.39; 95% CI:1.07-1.79;p = 0.012) compared to the AMG high-group.Conclusion: Our findings suggest AMG, an easily accessible novel biomarker, is an independent prognostic factor for survival in patients with advanced cancer treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"657-665"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report. 埃夫加替莫德治疗派姆单抗诱导的心肌炎、肌炎和重症肌无力重叠综合征（IM3OS） 1例

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI: 10.1080/1750743X.2025.2517522

Stephanie S Cobelas-Cartagena, Emilio Amigo-Otero, Victoria García-Samblas, Jesus Flores-Raposo, Silvia Rodrigo-Herrero, Juan Bayo-Calero

引用次数: 0

Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma. 评价莫加单抗治疗原发性皮肤t细胞淋巴瘤的疗效。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-24 DOI: 10.1080/1750743X.2025.2520153

M Oymanns, K Elsayad, L Wilms, F Dimmers, M Daum-Marzian, R Abu-Dawud, M Motiei, C Assaf

{"title":"Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.","authors":"M Oymanns, K Elsayad, L Wilms, F Dimmers, M Daum-Marzian, R Abu-Dawud, M Motiei, C Assaf","doi":"10.1080/1750743X.2025.2520153","DOIUrl":"10.1080/1750743X.2025.2520153","url":null,"abstract":"Mogamulizumab is a humanized monoclonal antibody targeting CCR4, a chemokine receptor expressed on T-cells, including malignant cells found in cutaneous T-cell lymphoma (CTCL). CTCL represents a heterogeneous group of skin lymphomas, with Mycosis Fungoides (MF) and Sézary Syndrome (SS) being the most common subtypes. Despite various treatment options, advanced stages of CTCL often present a challenge, with limited long-term therapeutic success. Mogamulizumab has demonstrated promise in treating relapsed or refractory CTCL.Clinical trials have shown that mogamulizumab effectively targets CCR4-positive malignant T-cells, leading to tumor regression and improved survival in patients with advanced CTCL. Its ability to deplete malignant T-cells, alongside its immunomodulatory effects, contributes to its potential as a critical therapeutic agent in this setting. In both, Phase III and real-world evidence studies, mogamulizumab has demonstrated an impressive overall response rate, progression-free survival in patients with MF and SS, along with a manageable safety profile.As a promising treatment option for patients with relapsed or refractory CTCL, mogamulizumab is currently being investigated in several ongoing clinical trials, exploring its efficacy both, as a monotherapy and in combination with other treatments. Continued research and long-term follow-up are essential to optimize its application across diverse clinical settings in CTCL.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"551-559"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging of brain metastases treated with immune checkpoint inhibitors. 免疫检查点抑制剂治疗脑转移瘤的影像学研究。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1080/1750743X.2025.2501931

Imren Özdamar, Sophie H A E Derks, Astrid A M van der Veldt

引用次数: 0

Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy. 接受免疫治疗的实体瘤患者胃肠道（GI）免疫相关不良事件的缓解策略

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-06 DOI: 10.1080/1750743X.2025.2516995

Angioletta Lasagna

引用次数: 0

Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary. 利来替尼研究中患者对头发再生的满意度：一个简单的语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-26 DOI: 10.1080/1750743X.2025.2513849

Rodney Sinclair, Ernest H Law, Xingqi Zhang, Fan Zhang, Lynne Napatalung, Samuel H Zwillich, Brett King, Natasha Mesinkovska

引用次数: 0

Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report. 非小细胞肺癌合并HBV和EBV感染患者的免疫检查点抑制剂相关性结肠炎1例报告

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-01 DOI: 10.1080/1750743X.2025.2527023

Chao Han, Sujuan Xi, Te Shi, Haiyan Yue

引用次数: 0

Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience. 纳武单抗在转移性头颈部鳞状细胞癌患者中的时间毒性：单一机构的经验。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI: 10.1080/1750743X.2025.2518913

Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo

{"title":"Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.","authors":"Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo","doi":"10.1080/1750743X.2025.2518913","DOIUrl":"10.1080/1750743X.2025.2518913","url":null,"abstract":"Background: Treatment of platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (r/mHNSCC) involves immune-checkpoint inhibitors. Time toxicity (TT) is an emerging metric with implications for patient quality of life and decision-making. We sought to evaluate TT associated with nivolumab in these patients.Methods: This is a retrospective single-institution review of patients with platinum-refractory r/mHNSCC seen at an academic cancer center between 1 January 2018 to 31 December 2022 in Ontario, Canada. Primary outcome is TT, defined as any number of days spent undergoing cancer-related activities.Results: Of 56 patients evaluated, median age was 63 years (33-85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1-109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders. TT accounted for only 4-6% for patients who survived more than a year.Conclusions: Our study provides an important and underexplored patient-centered metric in TT, especially in the context of incurable HNSCC with abysmal survival outcome. Our findings suggest that TT varies significantly between responders and non-responders. Duration of TT should be discussed with patients in shared decision-making when discussing palliative nivolumab.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"577-583"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0